Patient baseline characteristics
| Total cohort (n=608) | Community GI clinic (n=446) | University liver clinic (n=162) | p Value | |
|---|---|---|---|---|
| Mean age (years) | 44±13 | 43±13 | 45±14 | 0.19 |
| Male | 56.9% | 59.6% | 49.4% | 0.02 |
| Asian | 96.2% | 99.8% | 86.4% | <0.0001 |
| HBeAg-positive | 32.5% | 35.9% | 24.2% | 0.01 |
| Baseline ALT, U/L | 47 (34–78) | 45 (32–77) | 51 (25–78) | 0.02 |
| Baseline HBV DNA, log10 IU/mL | 5.3 (4.2–7.3) | 5.3 (4.4–7.1) | 5.0 (4.0–7.5) | 0.07 |
| Cirrhosis | 6.9% | 5.4% | 11.1% | 0.01 |
| Months to treatment initiation | 2 (1–7) | 2 (1–8) | 1 (1–3) | 0.002 |
| Follow-up of untreated patients | 17 (1–40) | 13 (1–40) | 21 (2–40) | 0.36 |
Values are presented as mean±SD, proportions, or median (IQR).
ALT, alanine aminotransferase; GI, gastroenterology; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus DNA.